Bionomics Investor Presentation Deck
Bionomics Outlook: Renewed Value-driving Trajectory
Bionomics
Bionomics
Balanced model with multiple value-driving clinical milestones expected in the next 4 - 6 quarters
E
BNC210's novel rapid onset formulation granted Fast Track designation for acute treatment of SAD
Established clinical proof-of-concept¹; expect Phase 2 topline data by YE'22
(
BNC210 Phase 2b ATTUNE PTSD study under way with Fast Track designation for 1H'23 topline data
Tablet formulation achieves exposure projected from pharmacometric analysis
Merck strategic partnership for treatment of cognitive impairment in Alzheimer's disease with two
compounds in clinical development
15
Diverse early-stage pipeline of partnering prospects targeting Kv and Nav ion channels for treatment of
schizophrenia and pain, respectively
Well-capitalized balance sheet driven by experienced leadership
SAD = Social Anxiety Disorder
PTSD Post-Traumatic Stress Disorder
1.
Wise T. et al., Biological Psychiatry 2020 (https://doi.org/10.1016/j.biopsych.2019.12.013); Perkins A. et al., Translational Psychiatry 2021 (https://doi.org/10.1038/s41398-020-01141-5)View entire presentation